Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (NCT03778229)

🧪 Interventions in This Study

• osimertinib (DRUG)
• savolitinib (DRUG)
• placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (90 Sites)

Showing the first 25 of 90 sites.

• Research Site — La Jolla, California
• Research Site — Los Angeles, California
• Research Site — Sacramento, California
• Research Site — Washington D.C., District of Columbia
• Research Site — Baltimore, Maryland
• Research Site — Boston, Massachusetts
• Research Site — Rochester, Minnesota
• Research Site — Brooklyn, New York
• Research Site — Philadelphia, Pennsylvania
• Research Site — Pittsburgh, Pennsylvania
• Research Site — Seattle, Washington
• Research Site — Barretos,
• Research Site — Curitiba,
• Research Site — Goiânia,
• Research Site — Porto Alegre,
• Research Site — Porto Alegre,
• Research Site — Rio de Janeiro,
• Research Site — Salvador,
• Research Site — São José do Rio Preto,
• Research Site — São Paulo,
• Research Site — São Paulo,
• Research Site — Calgary, Alberta
• Research Site — Edmonton, Alberta
• Research Site — Newmarket, Ontario
• Research Site — North York, Ontario

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Carcinoma

• Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment — Orlando, Florida
• Savolitinib vs. Sunitinib in MET-driven PRCC. — La Jolla, California
• Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer — St Louis, Missouri
• Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC — Huntsville, Alabama
• Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy — Fullerton, California

Explore by condition: All Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.